A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199
A Phase 1 Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of ABT-199
Sponsor: AbbVie
A PHASE1 clinical study on Non-Hodgkin's Lymphoma, this trial is completed. The trial is conducted by AbbVie and has accumulated 6 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Dec 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AbbVie
- Genentech, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .